Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
Oncology startups are raking in lion's share of early-stage capital and recent M&A's have also been heavily weighted toward oncology. Is too much capital going to overcome cancer?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Enlibrium's technology, licensed out of UCLA, will use diabetes drug metformin to shut down energy production in cancer cells - providing a potentially new frontline treatment for the disease.
San DIego-based tech and life sciences investor Avalon Venture looks to be raising its largest fund to date at $300 million.
Avalon and GSK's three new startups - Adrenergics, CadheRx Therapeutics and Calporta Therapeutics will each receive up to $10 million in Series A financing.
San Diego firm Avalon Ventures has rolled out two more biotech startups in its unique partnerhip with GlaxoSmithKline, according to a new statement. The new companies, Silarus Therapeutics and Thyritope Biosciences, will each receive $10 million in Series A funding from this Avalon-GSK partnership. Announced more than a year ago, the venture firm and its big […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The $495 million innovation collaboration between GlaxoSmithKline and early-stage investor Avalon Ventures has produced its first fruits in the form of a company initially focused on treating celiac disease. Sitari Pharmaceuticals launched today with a $10 million Series A from Avalon and GSK and technology from Stanford University. It’s still in the early discovery phase, […]
A California investment firm known most recently for its stake in Zynga (NASDAQ:ZNGA) has quickly raised $201.6 million for its 10th fund and could continue raising up to $250 million, according to a U.S. Securities and Exchange Commission filing made last week. According to the filing, Avalon planned to raise at least $200 million but […]